PMID- 20848892 OWN - NLM STAT- In-Process DA - 20100920 IS - 1000-0607 (Print) IS - 1000-0607 (Linking) VI - 35 IP - 3 DP - 2010 Jun TI - [Protective effect of "neiguan" (PC 6)-electroacupuncture preconditioning on the myocardium in myocardial ischemia/reperfusion rats] PG - 182-7 AB - OBJECTIVE: To investigate the effects of "Neiguan" (PC 6)-electroacupunture (EA) preconditioning on the myocardium and its mast cells in myocardial ischemia/reperfusion (MI/R) rats. METHODS: Eighteen male SD rats were randomly assigned to sham group, model (IR) group and EA group (n=6/ group). MI/R model was established by occlusion of the descending anterior branch of the coronary artery. Blood samples were taken from the femoral vein before MI (T0), EA for 30 min (T1), 30 min after MI (T2), 30 min after MI/R (T3) and 120 min after MI/R (T4) for assaying serum tumor necrosis factor (TNF)-alpha and histamine contents by using ELISA. Serum lactate dehydrogenase (LDH) and creatinkinase isoenzyme (CK-MB) levels were measured at T0, T3 and T4 by using an automatic biochemistry analyzer. The infarct size was detected by Evan's blue and tetrazolium chloride (TTC) staining. Myocardial TNF-alpha and histamine contents were detected by ELISA. The percentage of mast cell degranulation was determined by toluidine blue staining. RESULTS: Following MI/R, serum LDH and CK-MB levels at phase T3 and T4, serum TNF-alpha and histamine contents at phase T2 and T3, and myocardial mast cell degranulation rate increased significantly, and myocardial TNF-alpha and histamine contents decreased in model group in comparison with pre-MI/R (P < 0.05). Compared with IR model group, serum LDH and CK-MB levels at phase T3 and T4, myocardial TNF-alpha and histamine contents all decreased significantly (P < 0.05), but serum TNF-al infarct size was remarkably smaller in EA group than that in IR model group (P < 0.05). CONCLUSION: "Neiguan" (PC 6)-EA preconditioning has a cardioprotective effect on the ischemia-reperfusion myocardium by promoting mast cell degranulation. AD - Department of Anesthesiology, The Affiliated Renji Hospital of Shanghai Jiaotong University Medical College, Shanghai 200127, China. ling198471@yahoo.cn FAU - Zhang, Jiang-ling AU - Zhang JL FAU - Chen, Jie AU - Chen J FAU - Wang, Xiang-rui AU - Wang XR FAU - Li, Wei-wei AU - Li WW FAU - Wang, Bei-lei AU - Wang BL FAU - Zhou, Jie AU - Zhou J LA - chi PT - English Abstract PT - Journal Article PL - China TA - Zhen Ci Yan Jiu JT - Zhen ci yan jiu = Acupuncture research / [Zhongguo yi xue ke xue yuan Yi xue qing bao yan jiu suo bian ji] JID - 8507710 SB - IM EDAT- 2010/09/21 06:00 MHDA- 2010/09/21 06:00 CRDT- 2010/09/21 06:00 PST - ppublish SO - Zhen Ci Yan Jiu. 2010 Jun;35(3):182-7. PMID- 20844345 OWN - NLM STAT- In-Process DA - 20100916 IS - 1536-3686 (Electronic) IS - 1075-2765 (Linking) VI - 17 IP - 5 DP - 2010 Sep-Oct TI - A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. PG - 476-86 AB - Nausea and vomiting are 2 of the most upsetting adverse reactions of chemotherapy. Current guidelines propose 5-hydroxytryptamine3 (5-HT3) receptor antagonists as a pharmacologic intervention for acute and delayed nausea and vomiting [chemotherapy-induced nausea and vomiting (CINV)] associated with moderately and highly emetogenic chemotherapy. Meanwhile, both postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting are challenging situations after surgeries and procedures. Prophylactic and therapeutic combinations of antiemetics are recommended in patients at high risk of suffering from PONV and postdischarge nausea and vomiting. Granisetron (Kytril) is a selective 5-HT3 receptor antagonist that does not induce or inhibit the hepatic cytochrome P-450 system in vitro. There are also 4 other antagonists of 5-HT3 receptor (dolasetron, ondansetron, palonosetron, and tropisetron) being metabolized via the CYP2D6 and are subject to potential genetic polymorphism. The launch of a new class of antiemetics, the substance P/neurokinin1 receptor antagonists, was attributed to the scientific update on the central generator responsible for emesis and role of substance P. There has been mounting interest in exploring integrative medicine, either acupuncture or acustimulation of P6 (Nei-Kuwan), to complement the western medicine for prevention and management of nausea and vomiting. The potential application of cannabinoids, either alone or in combination with other agents of different mechanism, could contribute further to improve outcome in CINV. Implementation of future treatment guidelines for more effective management of CINV and PONV could certainly improve the efficacy and outcome of cancer and postoperative care. AD - Department of Anesthesiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. ehsu@mednet.ucla.edu FAU - Hsu, Eric S AU - Hsu ES LA - eng PT - Journal Article PL - United States TA - Am J Ther JT - American journal of therapeutics JID - 9441347 SB - IM EDAT- 2010/09/17 06:00 MHDA- 2010/09/17 06:00 CRDT- 2010/09/17 06:00 AID - 10.1097/MJT.0b013e3181ea7821 [doi] AID - 00045391-201009000-00006 [pii] PST - ppublish SO - Am J Ther. 2010 Sep-Oct;17(5):476-86. PMID- 20824841 OWN - NLM STAT- In-Data-Review DA - 20100908 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 9 DP - 2010 TI - Non-hormonal interventions for hot flushes in women with a history of breast cancer. PG - CD004923 AB - BACKGROUND: Hot flushes are common in women with a history of breast cancer. Hormonal therapies are known to reduce these symptoms but are not recommended in women with a history of breast cancer due to their potential adverse effects. The efficacy of non-hormonal therapies is still uncertain. OBJECTIVES: To assess the efficacy of non-hormonal therapies in reducing hot flushes in women with a history of breast cancer. SEARCH STRATEGY: We searched the Cochrane Breast Cancer Group Specialised Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE, LILACS, CINAHL, PsycINFO (August 2008) and WHO ICTRP Search Portal. We handsearched reference lists of reviews and included articles, reviewed conference proceedings and contacted experts. SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing non-hormonal therapies with placebo or no therapy for reducing hot flushes in women with a history of breast cancer. DATA COLLECTION AND ANALYSIS: Two authors independently selected potentially relevant studies, decided upon their inclusion and extracted data on participant characteristics, interventions, outcomes and the risk of bias of included studies. MAIN RESULTS: Sixteen RCTs met our inclusion criteria. We included six studies on selective serotonin (SSRI) and serotonin-norepinephrine (SNRI) reuptake inhibitors, two on clonidine, one on gabapentin, two each on relaxation therapy and homeopathy, and one each on vitamin E, magnetic devices and acupuncture. The risk of bias of most studies was rated as low or moderate. Data on continuous outcomes were presented inconsistently among studies, which precluded the possibility of pooling the results. Three pharmacological treatments (SSRIs and SNRIs, clonidine and gabapentin) reduced the number and severity of hot flushes. One study assessing vitamin E did not show any beneficial effect. One of two studies on relaxation therapy showed a significant benefit. None of the other non-pharmacological therapies had a significant benefit. Side-effects were inconsistently reported. AUTHORS' CONCLUSIONS: Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer. AD - Department of Internal Medicine, Evidence Based Health Care Program, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Lira 44, Decanato Primer piso, Santiago, Chile. FAU - Rada, Gabriel AU - Rada G FAU - Capurro, Daniel AU - Capurro D FAU - Pantoja, Tomas AU - Pantoja T FAU - Corbalan, Javiera AU - Corbalan J FAU - Moreno, Gladys AU - Moreno G FAU - Letelier, Luz M AU - Letelier LM FAU - Vera, Claudio AU - Vera C LA - eng PT - Journal Article DEP - 20100908 PL - England TA - Cochrane Database Syst Rev JT - Cochrane database of systematic reviews (Online) JID - 100909747 SB - IM EDAT- 2010/09/09 06:00 MHDA- 2010/09/09 06:00 CRDT- 2010/09/09 06:00 AID - 10.1002/14651858.CD004923.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2010 Sep 8;9:CD004923. PMID- 20811914 OWN - NLM STAT- Publisher DA - 20100902 IS - 1433-7339 (Electronic) IS - 0941-4355 (Linking) DP - 2010 Sep 3 TI - Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. AB - PURPOSE: Despite significant advances in antiemetic management, almost 50% of cancer patients still experience nausea and vomiting during treatment. The goal of antiemetic therapy is complete prevention of treatment-induced nausea and/or vomiting (TINV); however, realisation of this goal remains elusive, thus supplementary strategies identifying patients at high risk must be employed in the interim. Consequently, we examined TINV incidence and its risk factors, including patient, clinical and pretreatment quality of life (QOL)/psychological factors. METHODS: Two hundred newly diagnosed cancer patients beginning combined treatment participated in this prospective, longitudinal, observational study. QOL (including TINV), psychological adjustment, and patient/clinical characteristics were examined at pretreatment, on-treatment (8 weeks +/- 1 week) and post-treatment. RESULTS: Overall, 62% of patients experienced TINV, with TIN incidence (60%) doubling that of TIV (27%). Eight independent risk factors predicted 73% of TIN incidence: high premorbid/anticipatory NV, moderately/highly emetogenic chemotherapy (M/HEC), longer treatment (>3 months), female gender, surgery prior to adjuvant chemotherapy +/- radiotherapy, private health insurance and low emotional functioning (pretreatment). Six independent risk factors predicted 77% of TIV incidence: premorbid/anticipatory vomiting, M/HEC, female gender, cancer resection and low role functioning (pretreatment). CONCLUSIONS: TINV still represents a very major concern for patients. Several pretreatment risk factors for the development of TIN and TIV, respectively, were identified. Patients about to undergo cancer treatment, particularly combined treatment involving emetogenic chemotherapy and surgery, should be screened for these factors with a view to modifying standard pretreatment/maintenance antiemetic therapy. Furthermore, and consistent with recent research, it is recommended that more comprehensive interventions combining antiemetics with other effective pharmacological (e.g. anxiolytics) and non-pharmacological approaches (e.g. acupuncture, relaxation techniques) be considered by clinicians in attempts to improve control of TIN and TIV (and overall QOL) for their patients. In this way, optimal holistic care will be ensured for cancer patients by clinicians providing conventional oncology treatment. AD - Faculty of Health Sciences (Psychology), Murdoch University, South Street, Murdoch, WA, 6150, Australia, cpirri@gmail.com. AU - Pirri C AU - Katris P AU - Trotter J AU - Bayliss E AU - Bennett R AU - Drummond P LA - ENG PT - JOURNAL ARTICLE DEP - 20100903 TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 EDAT- 2010/09/03 06:00 MHDA- 2010/09/03 06:00 CRDT- 2010/09/03 06:00 PHST- 2009/10/01 [received] PHST- 2010/08/16 [accepted] PHST- 2010/09/03 [aheadofprint] AID - 10.1007/s00520-010-0982-y [doi] PST - aheadofprint SO - Support Care Cancer. 2010 Sep 3. PMID- 20615861 OWN - NLM STAT- MEDLINE DA - 20100709 DCOM- 20100830 IS - 0964-5284 (Print) IS - 0964-5284 (Linking) VI - 28 IP - 2 DP - 2010 Jun TI - Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PG - 83-93 AB - The STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) were published in five journals in 2001 and 2002. These guidelines, in the form of a checklist and explanations for use by authors and journal editors, were designed to improve reporting of acupuncture trials, particularly the interventions, thereby facilitating their interpretation and replication. Subsequent reviews of the application and impact of STRICTA have highlighted the value of STRICTA as well as scope for improvements and revision. To manage the revision process a collaboration between the STRICTA Group, the CONSORT Group and the Chinese Cochrane Centre was developed in 2008. An expert panel with 47 participants was convened that provided electronic feedback on a revised draft of the checklist. At a subsequent face-to-face meeting in Freiburg, a group of 21 participants further revised the STRICTA checklist and planned dissemination. The new STRICTA checklist, which is an official extension of CONSORT, includes 6 items and 17 subitems. These set out reporting guidelines for the acupuncture rationale, the details of needling, the treatment regimen, other components of treatment, the practitioner background and the control or comparator interventions. In addition, and as part of this revision process, the explanations for each item have been elaborated, and examples of good reporting for each item are provided. In addition, the word 'controlled' in STRICTA is replaced by 'clinical', to indicate that STRICTA is applicable to a broad range of clinical evaluation designs, including uncontrolled outcome studies and case reports. It is intended that the revised STRICTA checklist, in conjunction with both the main CONSORT statement and extension for non-pharmacological treatment, will raise the quality of reporting of clinical trials of acupuncture. AD - Department of Health Sciences, University of York, Heslington, York YO10 5DD, UK. hm18@york.ac.uk FAU - MacPherson, Hugh AU - MacPherson H FAU - Altman, Douglas G AU - Altman DG FAU - Hammerschlag, Richard AU - Hammerschlag R FAU - Li, Youping AU - Li Y FAU - Wu, Taixiang AU - Wu T FAU - White, Adrian AU - White A FAU - Moher, David AU - Moher D CN - STRICTA Revision Group LA - eng GR - Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100608 PL - England TA - Acupunct Med JT - Acupuncture in medicine : journal of the British Medical Acupuncture Society JID - 9304117 SB - IM CIN - Acupunct Med. 2010 Jun;28(2):63. PMID: 20615857 MH - Acupuncture Therapy/*methods/*standards MH - Controlled Clinical Trials as Topic/*standards MH - Guidelines as Topic MH - Humans MH - Peer Review, Research/*standards MH - Periodicals as Topic/standards MH - Practice Guidelines as Topic MH - Publishing/*standards MH - Quality of Health Care MH - Research Design/standards MH - United States IR - Altman DG FIR - Altman, Douglas G IR - Moher D FIR - Moher, David IR - MacPherson H FIR - MacPherson, Hugh IR - Hammerschlag R FIR - Hammerschlag, Richard IR - Li Y FIR - Li, Youping IR - Wu T FIR - Wu, Taixiang IR - Birch S FIR - Birch, Stephen IR - Boutron I FIR - Boutron, Isabelle IR - Bovey M FIR - Bovey, Mark IR - Fei Y FIR - Fei, Yutong IR - Gagnier J FIR - Gagnier, Joel IR - Hopewell S FIR - Hopewell, Sally IR - Hopwood V FIR - Hopwood, Val IR - Jena S FIR - Jena, Susanne IR - Linde K FIR - Linde, Klaus IR - Liu J FIR - Liu, Jianping IR - Trinh K FIR - Trinh, Kien IR - Veitch E FIR - Veitch, Emma IR - White A FIR - White, Adrian IR - Yamashita H FIR - Yamashita, Hitoshi EDAT- 2010/07/10 06:00 MHDA- 2010/08/31 06:00 CRDT- 2010/07/10 06:00 PHST- 2010/06/08 [aheadofprint] AID - aim.2009.001370 [pii] AID - 10.1136/aim.2009.001370 [doi] PST - ppublish SO - Acupunct Med. 2010 Jun;28(2):83-93. Epub 2010 Jun 8. PMID- 20536094 OWN - NLM STAT- MEDLINE DA - 20100611 DCOM- 20100916 IS - 1293-8505 (Print) IS - 1293-8505 (Linking) IP - 161 DP - 2010 Jun TI - [Nursing research on using acupressure wrist bands in oncology] PG - 39-40 AD - Centre de lutte contre le cancer Claudius Regaud, Toulouse. FAU - Clementai, Severine AU - Clementai S FAU - Delord, Jean-Pierre AU - Delord JP FAU - Gosselin, Chantal AU - Gosselin C LA - fre PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial TT - Recherche infirmiere sur l'utilisation des bracelets d'acupression en cancerologie. PL - France TA - Rev Infirm JT - Revue de l'infirmiere JID - 1267175 RN - 0 (Antiemetics) RN - 0 (Antineoplastic Agents) SB - N MH - Acupressure/*instrumentation/*nursing MH - Antiemetics/therapeutic use MH - Antineoplastic Agents/*adverse effects/therapeutic use MH - *Clinical Nursing Research MH - Combined Modality Therapy MH - Humans MH - Nausea/chemically induced/*nursing MH - Neoplasms/drug therapy/*nursing MH - Pilot Projects MH - Prospective Studies MH - Vomiting/chemically induced/*nursing EDAT- 2010/06/12 06:00 MHDA- 2010/09/18 06:00 CRDT- 2010/06/12 06:00 PST - ppublish SO - Rev Infirm. 2010 Jun;(161):39-40. PMID- 20489193 OWN - NLM STAT- MEDLINE DA - 20100521 DCOM- 20100914 IS - 1549-490X (Electronic) IS - 1083-7159 (Linking) VI - 15 Suppl 2 DP - 2010 TI - Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. PG - 19-23 AB - Integrative oncology is the synthesis of mainstream cancer care and evidence-based complementary therapies. Complementary strategies include massage therapies, acupuncture, fitness, and mind-body techniques, which take advantage of the reciprocal relationship between the mind and body. Neuropathic pain--and pain more generally--is part of a complex process involving the whole physical and psychosocial being, therefore requiring an integrative management approach. Several studies have demonstrated, for example, that social context plays an important role in the perception of pain and that a patient's coping strategies can influence the persistence of pain. In this article, we briefly describe research illustrating the promise of integrative approaches for the treatment of cancer-related neuropathic pain. AD - Memorial Sloan-Kettering Cancer Center, New York, New York, USA. FAU - Cassileth, Barrie R AU - Cassileth BR FAU - Keefe, Francis J AU - Keefe FJ LA - eng GR - R01 CA100771/CA/NCI NIH HHS/United States GR - R01CA131148/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review PL - United States TA - Oncologist JT - The oncologist JID - 9607837 SB - IM MH - Acupuncture Therapy MH - Cognitive Therapy MH - Humans MH - Hypnosis MH - Massage MH - Neoplasms/*complications MH - Neuralgia/*etiology/psychology/*therapy RF - 23 EDAT- 2010/05/28 06:00 MHDA- 2010/09/15 06:00 CRDT- 2010/05/22 06:00 AID - 15/suppl_2/19 [pii] AID - 10.1634/theoncologist.2009-S504 [doi] PST - ppublish SO - Oncologist. 2010;15 Suppl 2:19-23. PMID- 20406930 OWN - NLM STAT- MEDLINE DA - 20100520 DCOM- 20100908 IS - 1527-7755 (Electronic) IS - 0732-183X (Linking) VI - 28 IP - 15 DP - 2010 May 20 TI - Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. PG - 2565-70 AB - PURPOSE: To determine whether acupuncture reduces pain and dysfunction in patients with cancer with a history of neck dissection. The secondary objective is to determine whether acupuncture relieves dry mouth in this population. PATIENTS AND METHODS: Patients at a tertiary cancer center with chronic pain or dysfunction attributed to neck dissection were randomly assigned to weekly acupuncture versus usual care (eg, physical therapy, analgesia, and/or anti-inflammatory drugs, per patient preference or physician recommendation) for 4 weeks. The Constant-Murley score, a composite measure of pain, function, and activities of daily living, was the primary outcome measure. Xerostomia, a secondary end point, was assessed using the Xerostomia Inventory. RESULTS: Fifty-eight evaluable patients were accrued and randomly assigned from 2004 to 2007 (28 and 30 patients on acupuncture and control arms, respectively). Constant-Murley scores improved more in the acupuncture group (adjusted difference between groups = 11.2; 95% CI, 3.0 to 19.3; P = .008). Acupuncture produced greater improvement in reported xerostomia (adjusted difference in Xerostomia Inventory = -5.8; 95% CI, -0.9 to -10.7; P = .02). CONCLUSION: Significant reductions in pain, dysfunction, and xerostomia were observed in patients receiving acupuncture versus usual care. Although further study is needed, these data support the potential role of acupuncture in addressing post-neck dissection pain and dysfunction, as well as xerostomia. AD - Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. pfisterd@mskcc.org FAU - Pfister, David G AU - Pfister DG FAU - Cassileth, Barrie R AU - Cassileth BR FAU - Deng, Gary E AU - Deng GE FAU - Yeung, K Simon AU - Yeung KS FAU - Lee, Jennifer S AU - Lee JS FAU - Garrity, Donald AU - Garrity D FAU - Cronin, Angel AU - Cronin A FAU - Lee, Nancy AU - Lee N FAU - Kraus, Dennis AU - Kraus D FAU - Shaha, Ashok R AU - Shaha AR FAU - Shah, Jatin AU - Shah J FAU - Vickers, Andrew J AU - Vickers AJ LA - eng GR - CA098792/CA/NCI NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20100420 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 SB - IM MH - Acupuncture Therapy/*methods MH - Aged MH - Female MH - Head and Neck Neoplasms/surgery MH - Humans MH - Male MH - Middle Aged MH - Neck Dissection/*adverse effects MH - Neck Pain/etiology/*therapy MH - Pain, Postoperative/etiology/*therapy MH - Xerostomia/complications/therapy PMC - PMC2881730 OID - NLM: PMC2881730 [Available on 05/20/11] EDAT- 2010/04/22 06:00 MHDA- 2010/09/09 06:00 CRDT- 2010/04/22 06:00 PMCR- 2011/05/20 PHST- 2010/04/20 [aheadofprint] AID - JCO.2009.26.9860 [pii] AID - 10.1200/JCO.2009.26.9860 [doi] PST - ppublish SO - J Clin Oncol. 2010 May 20;28(15):2565-70. Epub 2010 Apr 20. PMID- 20041291 OWN - NLM STAT- MEDLINE DA - 20100524 DCOM- 20100907 IS - 1573-6830 (Electronic) IS - 0272-4340 (Linking) VI - 30 IP - 4 DP - 2010 May TI - The genome-wide expression profile of electroacupuncture in DNP-KLH immunized mice. PG - 631-40 AB - Previously, we demonstrated that electoracupuncture (EA) suppressed allergic reactions in DNP-KLH immunized mice. In this study, the mechanisms by which EA induces immunomodulation in the immunized mice were evaluated by genome-wide microarray analysis. The anti-allergic effects of EA in DNP-KLH immunized mice were confirmed by analyzing antigen specific IgE using ELISA. Microarray analysis, followed by real time RT-PCR validation, revealed that Th1 and Th17 cytokine-, opioid peptide-, and anti-apoptosis-related genes were up-regulated upon treatment with EA. In addition, significant decreases in Th2 cytokine-, MAPK signaling pathway-, and apoptosis-related genes were observed following EA treatment. AD - Brain Korea 21 Project for Medical Science, Yonsei University, Seoul, 130-701, Republic of Korea. FAU - Sohn, Sung-Hwa AU - Sohn SH FAU - Kim, Sun Kwang AU - Kim SK FAU - Ko, Eunjung AU - Ko E FAU - Lee, Youngseop AU - Lee Y FAU - Chung, Hwan-Suck AU - Chung HS FAU - Lee, Hyojung AU - Lee H FAU - Kim, Hyunseong AU - Kim H FAU - Hwang, Deok-Sang AU - Hwang DS FAU - Nam, Sangsoo AU - Nam S FAU - Bae, Hyunsu AU - Bae H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20091230 PL - United States TA - Cell Mol Neurobiol JT - Cellular and molecular neurobiology JID - 8200709 RN - 0 (Adjuvants, Immunologic) RN - 0 (Cytokines) RN - 0 (Uncoupling Agents) RN - 0 (keyhole-limpet hemocyanin) RN - 37341-29-0 (Immunoglobulin E) RN - 51-28-5 (2,4-Dinitrophenol) RN - 9013-72-3 (Hemocyanin) SB - IM MH - 2,4-Dinitrophenol/immunology MH - Adjuvants, Immunologic MH - Animals MH - Cytokines/immunology MH - *Electroacupuncture MH - Female MH - Gene Expression Profiling/*methods MH - *Genome MH - Hemocyanin/immunology MH - Humans MH - Hypersensitivity, Immediate/chemically induced/*therapy MH - Immunoglobulin E/immunology MH - Mice MH - Mice, Inbred BALB C MH - Multigene Family MH - Oligonucleotide Array Sequence Analysis MH - Random Allocation MH - Reproducibility of Results MH - Uncoupling Agents EDAT- 2009/12/31 06:00 MHDA- 2010/09/08 06:00 CRDT- 2009/12/31 06:00 PHST- 2009/10/12 [received] PHST- 2009/12/11 [accepted] PHST- 2009/12/30 [aheadofprint] AID - 10.1007/s10571-009-9487-y [doi] PST - ppublish SO - Cell Mol Neurobiol. 2010 May;30(4):631-40. Epub 2009 Dec 30.